MOSCOW, 11 Mar – RIA Novosti. Several European countries have suspended the use of the coronavirus vaccine created by AstraZeneca in collaboration with the University of Oxford.
This happened amid reports of possible blood clots in the vaccinated.
The Austrian authorities were the first to suspend the use of the drug. This happened after one of the vaccinated died, and the other developed thromboembolism (blockage of the vessel by a detached thrombus. – Ed.) Of the pulmonary artery.
Denmark, Norway and Iceland followed the example of Austria. The pause in the use of the drug will continue until the European Medicines Agency (EMA) clarifies whether the vaccine actually causes blood clots.
Estonia, Lithuania, Luxembourg, Cyprus and Latvia have suspended the use of the problematic batch of AstraZeneca. Italy also banned one controversial party.
A case of thrombosis after vaccination was also detected in the Netherlands. As stated in the Lareb center, the patient was not injured, he did not need hospitalization. The investigation of the incident will continue. No decisions have been made in Germany yet, but they are studying the situation.
The European Medicines Agency said the benefits of using AstraZeneca outweigh the risks. As emphasized in the statement released the day before by the regulator, there is no scientific evidence so far that the reported incidents can be associated with the vaccination. The manufacturer himself stated about the safety of the drug.
Currently, four vaccines are authorized on the EU market: Pfizer / BioNTech (purchase of up to 600 million doses), Moderna (two contracts up to 460 million doses), AstraZeneca (up to 400 million doses) and Johnson & Johnson (purchase of 400 million doses with the option of additional purchase of another 200 million ).